B cell and antibody responses after treatment
The average change rates of CD19At the initiation of the study treatment, SARS-CoV-2 antibodies in three patients were positive. The durations from symptom onset to the initiation of the study treatment for these patients were seven, eleven, and thirteen days, respectively. Among patients whose antibodies were negative at treatment initiation, there was a 75.0% (3/4) positivity rate for SARS-CoV-2 antibodies in the control group, 83.3% (5/6) in the demeclocycline 150 mg group, and 100% (2/2) in the demeclocycline 300 mg group on day 8 of the study treatment. These results suggest that B cell counts and SARS-CoV-2 antibodies slightly increased in each group.